Vancomycin dosing in high-intensity continuous renal replacement therapy: A retrospective cohort study.
CVVHD
continuous renal replacement therapy
drug monitoring
vancomycin
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
02
05
2023
received:
11
01
2023
accepted:
04
05
2023
pubmed:
17
7
2023
medline:
17
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
An inverse relationship exists between vancomycin serum concentrations and the intensity of continuous renal replacement therapy (CRRT), reflected through the dialysate flow rate (DFR). There remains a lack of evidence to guide initial vancomycin dosing in the setting of high-intensity CRRT (i.e., DFR >30 mL/kg/h). Additionally, recommendations for pharmacokinetic monitoring of vancomycin have transitioned from a trough-based to area under the curve (AUC)-based dosing strategy to optimize efficacy and safety. Therefore, an improved understanding of the impact of CRRT intensity on AUC/MIC (minimum inhibitory concentration) has the potential to enhance vancomycin dosing in this patient population. The goal of this study is to evaluate current vancomycin dosing strategies and achievement of pharmacokinetic targets in patients on high-intensity CRRT. This was a single-center, retrospective cohort study of adult critically ill patients admitted to Houston Methodist Hospital between May 2019 and October 2021 and received vancomycin therapy while on high-intensity CRRT. High-intensity CRRT was defined by a DFR that was both ≥3 L/h and >30 mL/kg/h. Depending on the initial vancomycin dosing strategy, patients were stratified into either the traditional (15 mg/kg/day) or enhanced (≥15 mg/kg/day) dosing group. The primary outcome was the percent of patients who attained steady-state AUC A total of 125 patients were included in the final analysis, 56 in the traditional and 69 in the enhanced dosing group. The primary end point occurred in 74% and 54% of patients in the enhanced and traditional dosing groups, respectively (p = 0.029). Therapeutic vancomycin trough levels (10-20 μg/mL) were more commonly achieved in the enhanced dosing group compared with the traditional dosing group (66.7% vs. 45%, p = 0.013). As DFR rose, increasingly higher doses of vancomycin, up to 27 mg/kg/day, were required to achieve the therapeutic targets. This is the first study to evaluate the influence of variable CRRT intensities on vancomycin AUC/MIC. Our findings suggest that vancomycin doses of ≥15 mg/kg/day are needed to achieve early therapeutic targets in patients on high-intensity CRRT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1015-1023Informations de copyright
© 2023 Pharmacotherapy Publications, Inc.
Références
Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care. 2008;12(2):R47. doi:10.1186/cc6863
Kim WY, Huh JW, Lim CM, Koh Y, Hong SB. A comparison of acute kidney injury classifications in patients with severe sepsis and septic shock. Am J Med Sci. 2012;344(5):350-356. doi:10.1097/MAJ.0b013e3182425ec3
Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Prac. 2013;2013:479730. doi:10.1155/2013/479730
Tiglis M, Peride I, Florea IA, et al. Overview of Renal Replacement Therapy Use in a General Intensive Care Unit. Int J Environ Res Public Health. 2022;19(4):2453. doi:10.3390/ijerph19042453
Karkar A, Ronco C. Prescription of CRRT: a pathway to optimize therapy. Ann Intensive Care. 2020;10(1):32. doi:10.1186/s13613-020-0648-y
Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol. 2003;14(4):1022-1030. doi:10.1097/01.asn.0000059863.48590.e9
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y
Kourtis AP, Hatfield K, Baggs J, et al. Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections - United States. MMWR Morb Mortal Wkly Rep. 2019;68(9):214-219. doi:10.15585/mmwr.mm6809e1
Prevention CfDCa. National and State Healthcare-Associated Infections Progress Report. 2020 Available from https://wwwcdcgov/hai/data/portal/progress-reporthtml Accessed September 21, 2021.
Schilling A, Neuner E, Rehm SJ. Vancomycin: a 50-something-year-old antibiotic we still don't understand. Cleve Clin J Med. 2011;78(7):465-471. doi:10.3949/ccjm.78a.10168
Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3):325-327. doi:10.1086/600877
van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734-744. doi:10.1128/aac.01568-12
Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864. doi:10.1093/ajhp/zxaa036
Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37(7):2268-2282. doi:10.1097/CCM.0b013e3181aab3d0
Jamal JA, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med. 2014;42(7):1640-1650. doi:10.1097/ccm.0000000000000317
Wahby KA, Cunmuljaj L, Mouabbi K, Almadrahi Z, Wilpula L. Evaluation of dosing strategies and trough concentrations of vancomycin in patients undergoing continuous venovenous hemofiltration. Pharmacotherapy. 2021;41(7):554-561. doi:10.1002/phar.2535
Akers KS, Cota JM, Chung KK, Renz EM, Mende K, Murray CK. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy. J Burn Care Res. 2012;33(6):e254-e262. doi:10.1097/BCR.0b013e31825042fa
Covajes C, Scolletta S, Penaccini L, et al. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents. 2013;41(3):261-266. doi:10.1016/j.ijantimicag.2012.10.018
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-c184. doi:10.1159/000339789
Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356(9223):26-30. doi:10.1016/s0140-6736(00)02430-2
Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002;30(10):2205-2211. doi:10.1097/00003246-200210000-00005
Warrillow S, Fisher C, Bellomo R. Correction and control of hyperammonemia in acute liver failure: the impact of continuous renal replacement timing, intensity, and duration. Crit Care Med. 2020;48(2):218-224. doi:10.1097/ccm.0000000000004153
Chaijamorn W, Jitsurong A, Wiwattanawongsa K, Wanakamanee U, Dandecha P. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents. 2011;38(2):152-156. doi:10.1016/j.ijantimicag.2011.04.010
Alhammad A, Reardon D, Anger K, DeGrado J. 934: Evaluation of vancomycin dosing and CVVH intensity on vancomycin trough concentrations attainment. Crit Care Med. 2014;42(12):A1585. doi:10.1097/01.ccm.0000458431.50328.5d
Frazee EN, Kuper PJ, Schramm GE, et al. Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations. Antimicrob Agents Chemother. 2012;56(12):6181-6185. doi:10.1128/aac.00459-12
Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The Emperor's new clothes: PRospective Observational Evaluation of the Association between initial VancomycIn Exposure and failure rates among ADult HospitalizEd Patients with Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clin Infect Dis. 2020;70(8):1536-1545. doi:10.1093/cid/ciz460
Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69(11):1881-1887. doi:10.1093/cid/ciz051
NP F. Vancomycin steady-state trough calculator. http://Vanco PK.com. Accessed Sep 11, 2021.
Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4(2):183-195. doi:10.1007/bf01086153
Fewel N. Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data. J Clin Pharm Ther. 2021;46(5):1426-1432. doi:10.1111/jcpt.13474
Neely MN, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309-316. doi:10.1128/aac.01653-13
Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50-57. doi:10.1016/j.addr.2014.05.016
Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J. 2012;42(1):23-29. doi:10.1111/j.1445-5994.2011.02459.x
Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother. 2001;47(2):246. doi:10.1093/jac/47.2.246
Hoff BM, Maker JH, Dager WE, Heintz BH. Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update. Ann Pharmacother. 2020;54(1):43-55. doi:10.1177/1060028019865873
Koyanagi M, Anning R, Loewenthal M, Martin JH. Vancomycin: audit of American guideline-based intermittent dose administration with focus on overweight patients. Br J Clin Pharmacol. 2020;86(5):958-965. doi:10.1111/bcp.14205
Lans PJ, Lao Y, Sporsem H, et al. Variability in vancomycin levels in an intensive care population explained by variability in clearance. Intensive Care Med Exp. 2015;3(Suppl 1):A629. doi:10.1186/2197-425X-3-S1-A629
DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004;58(3):259-268. doi:10.1111/j.1365-2125.2004.02143.x
Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5):666-675. doi:10.1093/cid/ciu398
Casapao AM, Lodise TP, Davis SL, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015;59(6):2978-2985. doi:10.1128/aac.03970-14
Zasowski EJ, Murray KP, Trinh TD, et al. Identification of vancomycin exposure-toxicity thresholds in Hospitalized patients receiving intravenous vancomycin. Antimicrob Agents Chemother. 2018;62(1):e01684-17. doi:10.1128/aac.01684-17